Use of t-bet positive pTreg cells as drug targets
By targeting T-bet+pTreg cells in the tumor microenvironment and combining T-bet and CD39 inhibitors with immune checkpoint inhibitors, the problems of poor selectivity and large side effects in existing tumor immunotherapy have been solved, achieving a more efficient anti-tumor immune response and fewer side effects.
CN119925607BActive Publication Date: 2026-07-03WESTLAKE UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- WESTLAKE UNIV
- Filing Date
- 2025-01-20
- Publication Date
- 2026-07-03
Smart Images
Figure CN119925607B_ABST
Abstract
The application discloses application of T-bet positive pTreg cells as a drug target and relates to the field of immunology. The application discloses that Treg cells in a tumor microenvironment are mainly T-bet positive pTreg cells, and by targeting these cells, it is expected to significantly improve the effect of immunotherapy, and meanwhile, reduce side effects of the immune system. Compared with traditional immunotherapy, the application precisely targets pTreg cells, enhances an anti-tumor immune response, especially by combining immunotherapy, will greatly improve the anti-tumor immune response, ensure immune homeostasis, and avoid autoimmune problems caused by systemic removal of Treg cells.
Need to check novelty before this filing date? Find Prior Art